Let's revolutionise diabetes treatment!
We are on the lookout for talent in oral formulation:
Are you a key player in revolutionising diabetes treatment? Will you join us in changing the life of millions of people with diabetes?And are you interested in building a growing research unit in Denmark becoming a part of the global leader in diabetes care?
With an aspiration to defeat diabetes by finding better methods of diabetes treatment, Novo Nordisk A/S is fully dedicated to research within oral formulations.
 | Based on our long-standing excellence within diabetes research and by building on our existing expertise in protein engineering, expression, and formulation, our ambition is to develop new break-through products with orally available versions of insulin and GLP-1. |
Situated in Måløv, Denmark, our research unit, Oral Protein Formulation, is dedicated to developing oral insulin and oral GLP-1. Whether you are an experienced manager or interested in developing and enhancing your specialist profile, our research unit is the right place for you to grow and make a difference.
Oral Protein Formulation is an ambitious and growing research and development organisation consisting of three departments; Oral Product & Process Development, Oral Formulation & Analytical Development, and Oral Formulation Research. The organisation is dedicated to executing cutting edge research in global collaboration with partners. We are on the lookout for talent within the following fields of research: formulation analysis, pilot production for early clinical trials of solid dosage forms. The process technologies are granulation, tablet compression, tablet coating and capsulation. Within Novo Nordisk, all employees have individual development plans, and our knowledge sharing is systematised in formalised professional and academic networks. |  |
You bring
- Expertise in oral formulation preferably with peptides/proteins
- A strong background in formulation of solid dosage forms and process technologies
- Experience in discovery research from industry with oral administration
We’ve got
- A world-class protein technology platform
- A highly motivated team of scientists engaged in diabetes research
- An exciting project pipeline
- A research campus in Copenhagen, Denmark, rated one of the most attractive workplaces for scientists’ world-wide (The Scientist, June 6, 2005).
Available positions
Currently, we have 22 vacant positions. Check them out.
About Novo Nordisk A/S Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 27,900 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. |
